Form 4: Elevation Oncology CEO Joseph Ferra Jr. Reports Stock Transactions
SEC Form 4 Filing
CEO Joseph Ferra Jr. of Elevation Oncology reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On May 15, 2025, Joseph J. Ferra Jr., CEO of Elevation Oncology, engaged in transactions involving the company's stock.
- Ferra acquired 6,250 shares of common stock through the vesting of restricted stock units (RSUs).
- He also disposed of 2,303 shares of common stock at a price of $0.2998 per share.
- Following these transactions, Ferra directly owns 137,152 shares of Elevation Oncology common stock and 68,750 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders may be interested in the CEO's stock transactions as an indicator of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| February 15, 2025 | 25% of the RSUs vested. |
| May 15, 2025 | Date of the reported stock transactions, including RSU vesting and stock disposal. |
| May 19, 2025 | Date of signature for the Form 4 filing. |
Keywords
Elevation Oncology, Joseph Ferra Jr., Form 4, Stock Transactions, Restricted Stock Units, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.